Gene · 5889
Papers3,668
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
701 to 720 of 3,668
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Genetic testing women with newly diagnosed breast cancer: What criteria are the most predictive of a positive test? | Cancer Med | 2023 | 36544278 | PubTator, text mining | PubMed |
| Population-based analysis of POT1 variants in a cutaneous melanoma case-control cohort. | J Med Genet | 2023 | 36539277 | PubTator, text mining | PubMed |
| PD-1 inhibitor plus anlotinib for metastatic castration-resistant prostate cancer: a real-world study. | Asian J Androl | 2023 | 36537376 | PubTator, text mining | PubMed |
| Prevalence and clinical implications of germline mutations among Jordanian patients with ovarian cancer. The Jordanian exploratory cancer genetics (Jo-ECAG) ovarian study. | Mol Genet Genomic Med | 2023 | 36537080 | PubTator, text mining | PubMed |
| Inherited rare variants in homologous recombination and neurodevelopmental genes are associated with increased risk of neuroblastoma. | EBioMedicine | 2023 | 36493725 | PubTator, text mining | PubMed |
| Interactive webtool for analyzing drug sensitivity and resistance associated with genetic signatures of cancer cell lines. | J Cancer Res Clin Oncol | 2023 | 36472769 | PubTator, text mining | PubMed |
| Hereditary breast cancer: syndromes, tumour pathology and molecular testing. | Histopathology | 2023 | 36468211 | PubTator, text mining | PubMed |
| RosettaDDGPrediction for high-throughput mutational scans: From stability to binding. | Protein Sci | 2023 | 36461907 | PubTator, text mining | PubMed |
| Clinical and psychological implications of secondary and incidental findings in cancer susceptibility genes after exome sequencing in patients with rare disorders. | J Med Genet | 2023 | 36446584 | PubTator, text mining | PubMed |
| A multicenter study of clinical impact of variant of uncertain significance reclassification in breast, ovarian and colorectal cancer susceptibility genes. | Cancer Med | 2023 | 36426404 | PubTator, text mining | PubMed |
| The clinical implications and molecular features of intrahepatic cholangiocarcinoma with perineural invasion. | Hepatol Int | 2023 | 36418844 | PubTator, text mining | PubMed |
| UK consensus recommendations for clinical management of cancer risk for women with germline pathogenic variants in cancer predisposition genes: RAD51C, RAD51D, BRIP1 and PALB2. | J Med Genet | 2023 | 36411032 | PubTator, text mining | PubMed |
| Return of individual genomic research results within the PRAEGNANT multicenter registry study. | Breast Cancer Res Treat | 2023 | 36409394 | PubTator, text mining | PubMed |
| Malignant Perivascular Epithelioid Cell Tumor (PEComa) of the Uterus as Part of the Hereditary Cancer Syndrome: A Case Diagnosed with Multiple Malignancies. | Turk Patoloji Derg | 2023 | 36367123 | PubTator, text mining | PubMed |
The prevalence of gene mutations in homologous recombination repair pathways in Japanese patients with metastatic castration-resistant prostate cancer in real-world clinical practice: The multi-institutional observational ZENSHIN study. | Cancer Med | 2023 | 36358026 | PubTator, text mining | PubMed |
| APOBEC3G protects the genome of human cultured cells and mice from radiation-induced damage. | FEBS J | 2023 | 36325681 | PubTator, text mining | PubMed |
| Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA. | Clin Cancer Res | 2023 | 36318705 | PubTator, text mining | PubMed |
| Somatic inactivation of breast cancer predisposition genes in tumors associated with pathogenic germline variants. | J Natl Cancer Inst | 2023 | 36315097 | PubTator, text mining | PubMed |
| Interdisciplinary risk counseling for hereditary breast and ovarian cancer: real-world data from a specialized center. | Arch Gynecol Obstet | 2023 | 36307613 | PubTator, text mining | PubMed |
| Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984. | J Clin Oncol | 2023 | 36256912 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/5889/papers?page=36